#ECTRIMS2015 – What Would You Like To Ask Genentech?



This year, Multiple Sclerosis News Today will be offering live, on-site coverage of the ECTRIMS conference in Barcelona Spain. Dr. Ana de Barros, PhD is attending the conference as the site’s correspondent and will have the opportunity to interview Genentech representatives on their recent breakthroughs in MS.

In an effort to connect our readers directly with one of the leading biotechnology companies committed to research in the multiple sclerosis field, we are asking you to tell us what you’d like to ask Genentech? We want to hear from you and be your voice at ECTRIMS!


  1. LYNNE HEAL says:

    Why have many died on MS drugs thats been promoted and where is the data ect of whats really been going on for decades where many are no longer with us after taking MS drugs ?

  2. Laura says:

    We know more about the window of opportunity for treatment in RRMS -what does the window of treatment opportunity for PPMS look like ? How far into disability might someone with ppms b on the EDSS and still benefit from a DMT.?

  3. Michael Springer says:

    I was diagnosed with RRMS in 2001. The medications and IVIG I received over the years have allowed me to regain more of my abilities and capacities than I could have hoped for. But, it seems as though the pharmaceutical industry is stuck on DMMs. When will we begin to see more information about the research being done to treat MS and demylination with stem cell therapies?

  4. Ed says:

    I have been diagnosed with either PPMS or SPMS. I’m considering switching from Aubagio to Rituxin. My questions:

    1.) If I am treated with Rituxin now would it make sense to also be treated with Ocrelizumab later when it clears FDA approval?

    2.) If not, any general projection when Ocrelizumab may be approved?

    3.) What are the side effects of Ocrelizumab?

    Thank you.

    • Cristian says:

      I’d like to ask about Ocrelizumab. What are the severe adverse effects observed in the latest (OPERA I and II) trials? Are they following up with any of the participants of those trials to evaluate the treatment’s longer-term results? And also, will Roche/Genentech submit it for review in Europe too, next year? Thank you 🙂 .

Leave a Comment

Your email address will not be published. Required fields are marked *